Canadian Cancer Trials Group Bulletins

General


New Director, Translational Laboratory Research Laboratory

Dr. Jeremy Squire will join the Canadian Cancer Trials Group as Director, Translational Laboratory Research. This appointment will become effective June 1, 2008. His responsibilities will include leadership in facilitating the determination of strategic directions in translational research, engagement of basic and translational laboratory-based researchers from across Canada with Canadian Cancer Trials Group activities, and facilitation of these research activities at the Disease Site Committee level.

Dr. Squire is currently the J. C. Boileau Grant Chair in Oncologic Pathology at the University of Toronto and a Senior Scientist in the Division of Applied Molecular Oncology at the Ontario Cancer Institute. Dr. Squire received his Bachelor of Science (1973) and Master's (1978) degrees from Queen Mary College, University of London. He completed his PhD in Medical Biophysics at the University of Toronto in 1988. A specific emphasis of his work has included molecular evaluations of prostate cancer, osteosarcoma, and leukemia. Dr. Squire will spend 50% of his time with the Canadian Cancer Trials Group in leading the activities described above, and 50% of his time with his own laboratory-based activities within the Department of Pathology and Molecular Medicine at Queen's University.

The enhancement of translational research is a prime strategic direction of the Canadian Cancer Trials Group. Over the past decade, the Group has developed strengths in correlative biology under the leadership of our Correlative Sciences / Tumour Biology Committee that has been led by our external chairs, who have included Drs. Peter Watson, Carolyn Compton and now Ming Tsao, as well as our Central Office Physician Coordinator, Dr. Lois Shepherd.